[1]
|
“Prostate Cancer Statistics,” 2012.
http://www.cdc.gov/cancer/prostate/statistics
|
[2]
|
V. T. DeVita, T. S. Lawrence and S. A. Rosenberg, “Cancer Principles and Practice of Oncology,” 2008.
|
[3]
|
N. Howlader, “SEER Stat Fact Sheets: Prostate,” 2012.
http://seer.cancer.gov/statfacts/html/prost.html
|
[4]
|
K. Lassi, N. A. Dawson, “Emerging Therapies in Castrate-Resistant Prostate Cancer,” Current Opinion in Oncology, Vol. 21, No. 3, 2009, pp. 260-265.
doi:10.1097/CCO.0b013e32832a1868
|
[5]
|
R. M. Attar, C. H. Takimoto and M. M. Gottardis, “Castration-Resistant Prostate Cancer: Locking up the Molecular Escape Routes,” Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3251-3255.
doi:10.1158/1078-0432.CCR-08-1171
|
[6]
|
D. R. Berthold, G. Pond, R. de Wit, et al., “Docetaxel plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival of Tax 327,” Journal of Clinical Oncology, Vol. 25, No. 18, 2007, pp. 242-245.
|
[7]
|
E. J. Small, et al., “Placebo-Controlled Phase III Trial of Immunologic Therapy,” Journal of Clinical Oncology, Vol. 24, No. 19, 2006, pp. 3089-3093.
doi:10.1200/JCO.2005.04.5252
|
[8]
|
K. Phillip, C. Higano, et al., “Sipuleucel-T Immunotherapy for Castration-Resistant,” New England Journal of Medicine, Vol. 363, No. 5, 2010, pp. 411-422.
doi:10.1056/NEJMoa1001294 PMid:20818862
|
[9]
|
C. S. Higano, et al., “Integrated Data from 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy with Sipuleucel-T in Advanced Prostate Cancer,” Cancer, Vol. 115, No. 16, 2009, pp. 3670-3679. doi:10.1002/cncr.24429
|
[10]
|
“United States Food and Drug Administration Package Insert,” 2012.
|
[11]
|
R. M. Attar, C. H. Takimoto and M. M. Gottardis, “Castration-Resistant Prostate Cancer: Locking up the Molecular Escape Routes,” Clinical Cancer Research, Vol. 15, No. 10, 2009, pp. 3251-3255.
doi:10.1158/1078-0432.CCR-08-1171
|
[12]
|
J. S. de Bono, et al., “Prednisone plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel Treatment: A Randomised Open-Label Trial,” Lancet, Vol. 376, No. 9746, 2010, pp. 1147-1154.
doi:10.1016/S0140-6736(10)61389-X
|
[13]
|
“National Institutes of Health. Clinical Trials. 20,” 2012.
http://clinicaltrials.gov/
|
[14]
|
G. Attard, et al., “Selective Blockade of Androgenic Steroid Synthesis by Novel Lyase Inhibitors as a Therapeutic Strategy for Treating Metastatic Prostate Cancer,” British Journal of Urology International, Vol. 96, No. 9, 2005, pp. 1241-1246. doi:10.1111/j.1464-410X.2005.05821.x
|
[15]
|
D. C. Danila, et al., “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients with Docetaxel-Treated Castration-Resistant Prostate Cancer,” Journal of Clinical Oncology, Vol. 28, No. 9, 2010, pp. 1481-149. doi:10.1200/JCO.2009.25.9259
|
[16]
|
J. S. de Bono, et al., “Abiraterone and Increased Survival in Metastatic Prostate Cancer,” New England Journal of Medicine, Vol. 364, No. 12, 2011, pp. 1995-2005.
doi:10.1056/NEJMoa1014618
|
[17]
|
C. Logothetis, “Effect of Abiraterone Acetate on Pain Control and Skeletal-Related Events in Patients with Metastatic Castration-Resistant Prostate Cancer Post Docetaxel: Results from the COU-AA-301 Phase III Study,” 2011.
|
[18]
|
K. Fizazi, et al., “Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy,” New England Journal of Medicine, Vol. 367, 2012, pp. 1187-1197.
|
[19]
|
C. J. Ryan, et al., “Interim Analysis (IA) Results of COU-AA-302, a Randomized, Phase III Study of Abiraterone Acetate (AA) in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC),” Journal of Clinical Oncology, Vol. 30, 2012.
|
[20]
|
F. Saad, et al., “A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma,” Journal of National Cancer Institute, Vol. 94, No. 19, 2002, pp. 1458-1468.
doi:10.1093/jnci/94.19.1458
|
[21]
|
K. P. Weinfurt, et al., “Effect of Zoledronic Acid on Pain Associated with Bone Metastasis in Patients with Prostate Cancer,” Annals of Oncology, Vol. 17, No. 6, 2006, pp. 286-289. doi:10.1093/annonc/mdl041
|
[22]
|
K. Fizazi, et al., “Denosumab versus Zoledronic Acid for Treatment of Bone Metastases in Men with Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study,” Lancet, Vol. 377, No. 9768, 2011, pp. 813-822.
doi:10.1016/S0140-6736(10)62344-6
|
[23]
|
M. Smith, et al., “Denosumab and Bone-Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial,” Lancet, Vol. 379, No. 9810, 2012, pp. 39-46. doi:10.1016/S0140-6736(11)61226-9
|
[24]
|
C. Parker, et al., “Updated Analysis of the Phase III, Double-Blind, Randomized, Multinational Study of Radium-223 Chloride in Castration-Resistant Prostate Cancer (CRPC) Patients with Bone Metastases (ALSYMPCA),” Journal of Clinical Oncology, Vol. 30, 2012.
|
[25]
|
S. Nilson, P. Strang, et al., “Bone-Targeted Radium-223 in Symptomatic, Hormone Refractory,” European Journal of Cancer, Vol. 48, No. 5, 2012, pp. 678-686.
|